Evidence-Based Management of Hodgkin's Disease: The Role of Autologous Stem Cell Transplantation

Aisenberg A.C. Problems in Hodgkin's disease management. Blood. 1999; 93: 761–779.

DeVita V.T. Jr , Mauch P.M. , Harris N.L. Hodgkin's disease. In: DeVita V.T. Jr , Hellman S. , Rosenberg S.A. , eds. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: JB Lippincott Co; 1997: 2242–2283.

Ng A.K. , Weeks J.C. , Mauch P.M. Decision analysis on alternative treatment strategies for favorable prognosis, early-stage Hodgkin's disease. J Clin Oncol. 1999; 17: 3577–3585.

Canellos G.P. , Anderson J.R. , Propert K.J. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 1478–1484.

Linch D.C. , Winfield D. , Goldstone A.H. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet. 1993; 341: 1051–1054.

Schmitz N. , Sextro M. , Pfistner B. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 2a.

Yuen A.R. , Rosenberg S.A. , Hoppe R.T. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. 1997; 89: 814–822.

Chopra R. , Linch D.C. , McMillan A.K. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol. 1992; 81: 197–202.

Chopra R. , McMillan A.K. , Linch D.C. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. Blood. 1993; 81: 1137–1145.

Jagannath S. , Armitage J.O. , Dicke K.A. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989; 7: 179–185.

Rapoport A.P. , Rowe J.M. , Kouides P.A. One hundred auto-transplants for relapsed or refractory Hodgkin's disease and lymphoma value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993; 11: 2351–2361.

Sweetenham J.W. , Taghipour G. , Milligan D. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant. 1997; 20: 745–752.

Wheeler C. , Eickhoff C. , Elias A. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997; 3: 98–106.

Reece D.E. , Barnett M.J. , Shepherd J.D. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP 16–213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995; 86: 451–456.

Longo D.L. , Duffey P.L. , Young R.C. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992; 10: 210–218.

Bonfante V. , Santoro A. , Viviani S. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997; 15: 528–534.

Prince H.M. , Crump M. , Imrie K. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol. 1996; 7: 1043–1049.

Moreau P. , Fleury J. , Brice P. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry. Bone Marrow Transplant. 1998; 21: 787–793.

Lazarus H.M. , Rowlings P.A. , Zhang M.J. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999; 17: 534–545.

André M. , Henry-Amar M. , Pico J.L. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Graffe de Moelle J Clin Oncol. 1999; 17: 222–229.

Sweetenham J.W. , Carella A.M. , Taghipour G. High-dose therapy and autologous stem- cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999; 17: 3101–3109.

Milpied N. , Fielding A.K. , Pearce R.M. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996; 14: 1291–1296.

Slavin S. , Nagler A. , Naparstek E. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91: 756–763.

Lancet J.E. , Rapoport A.P. , Brasacchio R. Autotransplantation for relapsed or refractory Hodgkin's disease: long term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998; 22: 265–271.

Arranz R. , Tomas J.F. , Gil-Fernandez J.J. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant. 1998; 21: 779–786.

Crump M. , Smith A.M. , Brandwein J. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993; 11: 704–711.

Horning S.J. , Chao N.J. , Negrin R.S. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997; 89: 801–813.

Brice P. , Bouabdallah R. , Moreau P. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Bone Marrow Transplant. 1997; 20: 21–26.

Abruzzese E. , Radford J.E. , Miller J.S. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999; 94: 1814–1819.

Reece D. Should high risk patients with Hodgkin's disease be singled out for heavier therapeutic regimens while low risk patients are spared such therapies? Leuk Lymphoma. 1995; 15(suppl 1): 19–21.

Reece D.E. , Nevill T.J. , Sayegh A. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant. 1999; 23: 1131–1138.

Bierman P.J. , Anderson J.R. , Freeman M.B. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol. 1996; 7: 151–156.

Nademanee A. , O'Donnell M.R. , Snyder D.S. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood. 1995; 85: 1381–1390.

Reece D.E. , Connors J.M. , Spinelli J.J. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood. 1994; 83: 1193–1199.

Canellos G.P. , Petroni G.R. , Barcos M. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol. 1995; 13: 2005–2011.

Straus D.J. , Gaynor J.J. , Myers J. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990; 8: 1173–1186.

Fermé C. , Bastion Y. , Brice P. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer. 1997; 80: 1124–1133.

Hasenclever D. , Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339: 1506–1514.

Bradley S.J. , Pearce R. , Taghipour G. First remission autologous bone marrow transplantation for Hodgkin's disease: preliminary EBMT data. Leuk Lymphoma. 1995; 15(suppl 1): 51–53.

Carella A.M. , Prencipe E. , Pungolino E. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma. 1996; 21: 63–70.

Sureda A. , Mataix R. , Hernandez-Navarro F. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group. Bone Marrow Transplant. 1997; 20: 283–288.

Nademanee A. , Molina A. , Fung H. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced stage Hodgkin's disease during first partial or complete remission. Biol Blood Marrow Transplant. 1999; 5: 292–298.

André M. , Henry-Amar M. , Blaise D. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood. 1998; 92: 1933–1940.

Federico M. , Clo V. , Carella A.M. High-dose therapy and autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. Leukemia. 1996; 10(suppl 2): 69–71.

Hoppe R.T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997; 8(suppl 1): 115–118.